Therapeutic antibodies

An isolated antibody or antigen-binding fragment thereof, comprising:

• (a) an immunoglobulin heavy chain variable region that comprises a heavy chain complementarity determining region 1 (VH CDR1) comprising the amino acid sequence set forth in SEQ ID NO:
• 2;
• and a heavy chain complementarity determining region 2 (VH CDR2) comprising the amino acid sequence set forth in SEQ ID NO:
• 3;
• a heavy chain complementarity determining region 3 (VH CDR3) comprising the amino acid sequence set forth in SEQ ID NO:
• 4;
• and (b) an immunoglobulin light chain variable region that comprises a light chain complementarity determining region 1 (VL CDR1) comprising the amino acid sequence set forth in SEQ ID NO:
• 6;
• a light chain complementarity determining region 2 (VL CDR2) comprising the amino acid sequence set forth in SEQ ID NO:
• 7;
• and a light chain complementarity determining region 3 (VL CDR3) comprising the amino acid sequence set forth in SEQ ID NO:
• 8;
• wherein the antibody or antigen-binding fragment thereof is capable of binding specifically:
• to a biantennary LeB/LeB antigen comprising Fuc4(Galβ1→3GlcNAc)2 [I] or A [Fucα1-2Galβ1-3(Fucα1-4)GlcNAc]2 [II],
• to a biantennary LeY/LeY antigen comprising Fuc4(Galβ1→4GlcNAc)2 [III] or [Fucα1-2Galβ1-4(Fucα1-3)GlcNAc]2 [IV],
• to a biantennary LeB/LeY antigen comprising Fuc2(Galβ1→3GlcNAc)[Fuc2(Galβ1→4GlcNAc)] [V], or [Fucα1-2Galβ1-3(Fucα1-4)GlcNAc][Fucα1-2Galβ1-4(Fucα1-3)GlcNAc] [VI],
• and to a biantennary LeY/LeB antigen comprising Fuc2(Galβ1l-4GlcNAc)[Fuc2(Galβ1-3GlcNAc)] [VII] or [Fucα1-2Galβ1-4(Fucα1-3)GlcNAc][Fucα1-2Galβ1-3(Fucα1-4)GlcNAc] [VIII],
• and wherein the antibody or antigen-binding fragment thereof does not bind specifically to a monoantennary Lex antigen that comprises Galβ1→4(Fucα1→3)GlcNAc [IX], or to a biantennary Lex antigen that comprises [Galβ1→4(Fucα1→3)GlcNAc]2 [X], or to a monoantennary LeA antigen that comprises Galβ1-3(Fucα1-4)GlcNAc [XI], or to a monoantennary H antigen type 2 that comprises Fucα1-2Galβ1-4GlcNAc [XII], or to a biantennary H antigen type 2 that comprises (Fucα1-2Galβ1-4GlcNAc)2 [XIII] or to a monoantennary H antigen type 1 that comprises Fucα1-2Galβ1-3GlcNAc [XIV].

An isolated antibody or antigen-binding fragment thereof, comprising:

• an immunoglobulin heavy chain variable region that comprises the amino acid sequence set forth in SEQ ID NO:
• 35;
• and an immunoglobulin light chain variable region that comprises the amino acid sequence set forth in SEQ ID NO:
• 5, wherein the antibody or antigen-binding fragment thereof is capable of binding specifically:
• to a biantennary LeB/LeB antigen comprising Fuc4(Galβ1→3GlcNAc)2 [I] or [Fucα1-2Galβ1-3(Fucα1-4)GlcNAc]2, [II],
• to a biantennary LeY/LeY antigen comprising Fuc4(Galβ1→4GlcNAc)2 [III] or [Fucα1-2Galβ1-4(Fucα1-3)GlcNAc]2 [IV],
• to a biantennary LeB/LeY antigen comprising Fuc2(Galβ1→3GlcNAc)[Fuc2(Galβ1→4GlcNAc)] [V], or [Fucα1-2Galβ1-3(Fucα1-4)GlcNAc][Fucα1-2Galβ1-4(Fucα1-3)GlcNAc] [VI],
• and to a biantennary LeY/LeB antigen comprising Fuc2(Galβ1-4GlcNAc)[Fuc2(Galβ1-3GlcNAc)] [VII] or [Fucα1-2Galβ1-4(Fucα1-3)GlcNAc][Fucα1-2Galβ1-3(Fucα1-4)GlcNAc] [VIII],
• and wherein the antibody or antigen-binding fragment thereof does not bind specifically to a monoantennary Lex antigen that comprises Galβ1→4(Fucα1→3)GlcNAc [IX], or to a biantennary Lex antigen that comprises [Galβ1→4(Fucα1→3)GlcNAc]2 [X], or to a monoantennary LeA antigen that comprises Galβ1-3(Fucα1-4)GlcNAc [XI], or to a monoantennary H antigen type 2 that comprises Fucα1-2Galβ1-4GlcNAc [XII], or to a biantennary H antigen type 2 that comprises (Fucα1-2Galβ1-4GlcNAc)2 [XIII] or to a monoantennary H antigen type 1 that comprises Fucα1-2Galβ1-3GlcNAc [XIV].